Antibodies and complement are key drivers of thrombosis
Author:
Stark KonstantinORCID, Kilani Badr, Stockhausen Sven, Busse Johanna, Schubert Irene, Tran Thuy-Duong, Gaertner FlorianORCID, Leunig AlexanderORCID, Pekayvaz Kami, Nicolai Leo, Fumagalli Valeria, Stermann Julia, Stephan Felix, David Christian, Müller Martin B., Heyman Birgitta, Lux Anja, da Palma Guerreiro Alexandra, Frenzel Lukas P., Schmidt Christoph Q., Dopler Arthur, Moser Markus, Chandraratne SueORCID, von Brühl Marie-Luise, Lorenz Michael, Korff Thomas, Rudelius Martina, Popp Oliver, Kirchner Marieluise, Mertins PhilippORCID, Nimmerjahn Falk, Iannacone Matteo, Sperandio MarkusORCID, Engelmann Bernd, Verschoor Admar, Massberg SteffenORCID
Reference116 articles.
1. The importance of natural IgM: scavenger, protector and regulator;Ehrenstein;Nat. Rev. Immunol.,2010 2. Therapeutic antibodies: market considerations, disease targets and bioprocessing;Elvin;Int. J. Pharm.,2013 3. Trial of Intravenous Immune Globulin in Dermatomyositis;Aggarwal;N. Engl. J. Med.,2022 4. Thromboembolic Events Associated with Bevacizumab plus Chemotherapy for Patients with Colorectal Cancer: A Meta-Analysis of Randomized Controlled Trials;Alahmari;Am. Health Drug Benefits,2016 5. Intravenous immune globulin and thromboembolic adverse events in patients with hematologic malignancy;Ammann;Blood,2016
|
|